Literature DB >> 27270758

Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Angelos G Rigopoulos1, Silke Daci2, Barbara Pfeiffer2, Konstadia Papadopoulou2, Anna Neugebauer2, Hubert Seggewiss2.   

Abstract

INTRODUCTION: Percutaneous alcohol septal ablation (PTSMA) is an established treatment for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). However, there is concern of a higher risk for ventricular tachyarrhythmias and sudden death due to the myocardial scar created after PTSMA. We investigated the possibility of increased ventricular arrhythmias and risk of sudden death after PTSMA in a subgroup of patients with an already implanted ICD. METHODS AND
RESULTS: Between 2009 and 2012, 239 PTSMAs were performed in 212 patients with HOCM. In 32 of those an ICD had already been implanted before PTSMA for primary (31 patients) or secondary (1 patient) prevention of sudden death. The maximum left ventricular outflow tract gradient (LVOTG) was reduced from 114 ± 39 mmHg before PTSMA to 23 ± 19 mmHg (P < 0.0001). Among clinical risk factors for sudden death, nonsustained ventricular tachycardia (VT), syncope and family history for sudden death were most common. After a median follow-up of 5.3 (IQR 4.3-5.7) years after PTSMA only one patient had ICD shocks (annual ICD discharge 0.6 %). In another 3 patients, with already documented nonsustained VTs as risk factor before ICD implantation, VT episodes that activated antitachycardic pacing were recorded. The annual appropriate ICD intervention including all events was 2.5 % and involved only patients with a very high estimated 5-year sudden death risk before PTSMA (>14.3 %).
CONCLUSIONS: In a selected high-risk patient cohort with HOCM ominous arrhythmic events seem to be rare and predominantly occur in patients with a very high estimated risk of sudden death before PTSMA.

Entities:  

Keywords:  Alcohol septal ablation; Hypertrophic obstructive cardiomyopathy; Implantable cardioverter defibrillator; Survival; Ventricular arrhythmia

Mesh:

Substances:

Year:  2016        PMID: 27270758     DOI: 10.1007/s00392-016-1005-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  35 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

2.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Perry M Elliott; Juan R Gimeno; María T Tomé; Jaymin Shah; Deirdre Ward; Rajesh Thaman; Jens Mogensen; William J McKenna
Journal:  Eur Heart J       Date:  2006-06-05       Impact factor: 29.983

3.  Ventricular tachycardia complicating alcohol septal ablation.

Authors:  Chester M Boltwood; Walter Chien; Thomas Ports
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

4.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

Authors:  Constantinos O'Mahony; Fatima Jichi; Menelaos Pavlou; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

5.  Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Yasuhiko Hori; Marehiko Ueda; Takashi Nakayama; Noriko Saegusa; Masae Uehara; Kwangho Lee; Tai Sekine; Masao Daimon; Yoshio Kobayashi; Nobusada Funabashi; Issei Komuro
Journal:  Int J Cardiol       Date:  2006-10-27       Impact factor: 4.164

6.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Steve R Ommen; Barry J Maron; Iacopo Olivotto; Martin S Maron; Franco Cecchi; Sandro Betocchi; Bernard J Gersh; Michael J Ackerman; Robert B McCully; Joseph A Dearani; Hartzell V Schaff; Gordon K Danielson; A Jamil Tajik; Rick A Nishimura
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

7.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Uma S Valeti; Rick A Nishimura; David R Holmes; Philip A Araoz; James F Glockner; Jerome F Breen; Steve R Ommen; Bernard J Gersh; A Jamil Tajik; Charanjit S Rihal; Hartzell V Schaff; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2007-01-04       Impact factor: 24.094

8.  Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population.

Authors:  Josef Veselka; Jan Krejčí; Pavol Tomašov; David Zemánek
Journal:  Eur Heart J       Date:  2014-01-24       Impact factor: 29.983

9.  Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Paul Sorajja; Steve R Ommen; David R Holmes; Joseph A Dearani; Charanjit S Rihal; Bernard J Gersh; Ryan J Lennon; Rick A Nishimura
Journal:  Circulation       Date:  2012-10-17       Impact factor: 29.690

10.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

Authors:  Frank A Cuoco; William H Spencer; Valerian L Fernandes; Christopher D Nielsen; Sherif Nagueh; J Lacy Sturdivant; Robert B Leman; J Marcus Wharton; Michael R Gold
Journal:  J Am Coll Cardiol       Date:  2008-11-18       Impact factor: 24.094

View more
  7 in total

Review 1.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 2.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 3.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.

Authors:  Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2017-08-24       Impact factor: 5.460

4.  Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Amelie Burghardt; Frank van Buuren; Zisis Dimitriadis; Tim Grübbel; Hubert Seggewiss; Smita Scholtz; Dieter Horstkotte; Lothar Faber
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

Review 5.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

6.  Preoperative myocardial fibrosis is associated with worse survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: A delayed enhanced cardiac magnetic resonance study.

Authors:  Youzhou Chen; Xingshan Zhao; Jiansong Yuan; Yan Zhang; Wei Liu; Shubin Qiao
Journal:  Front Cardiovasc Med       Date:  2022-08-11

7.  Prognostic Effect of Underlying Chronic Kidney Disease and Renal Replacement Therapy on the Outcome of Patients after Out-of-Hospital Cardiac Arrest: A Nationwide Observational Study.

Authors:  Won Yang; Jae-Guk Kim; Gu-Hyun Kang; Yong-Soo Jang; Wonhee Kim; Hyun-Young Choi; Yoonje Lee
Journal:  Medicina (Kaunas)       Date:  2022-03-18       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.